Targeting cancer cells and tumor microenvironment in preclinical and clinical models of hodgkin lymphoma using the dual PI3Kδ/γ inhibitor RP6530

…, S Serio, FM Consonni, A Maeda, S Viswanadha… - Clinical Cancer …, 2019 - AACR
Purpose: Tumor-associated macrophages (TAMs) and the hyperactivation of the PI3K/AKT
pathway are involved in the pathogenesis of Hodgkin lymphoma and affect disease outcome. …

[HTML][HTML] Phase I/Ib study of tenalisib (RP6530), a dual PI3K δ/γ inhibitor in patients with relapsed/refractory T-cell lymphoma

…, Y Oki, PJ Barde, A Nair, KV Routhu, S Viswanadha… - Cancers, 2020 - mdpi.com
Tenalisib (RP6530), a dual phosphoinositide 3-kinase δ/γ inhibitor was evaluated in a phase
I/Ib study for maximum tolerated dose (MTD), pharmacokinetics, and efficacy in patients …

Repurposing of a drug scaffold: Identification of novel sila analogues of rimonabant as potent antitubercular agents

…, B Swetha, S Veeraraghavan, S Viswanadha… - European Journal of …, 2016 - Elsevier
The structural similarity between an MmpL3 inhibitor BM212, and a cannabinoid receptor
modulator rimonabant, prompted us to investigate the anti-tubercular activity of rimonabant and …

Simultaneous quantification of lenalidomide, ibrutinib and its active metabolite PCI-45227 in rat plasma by LC–MS/MS: Application to a pharmacokinetic study

S Veeraraghavan, S Viswanadha, S Thappali… - … of pharmaceutical and …, 2015 - Elsevier
Efficacy assessments using a combination of ibrutinib and lenalidomide necessitate the
development of an analytical method for determination of both drugs in plasma with precision. A …

[HTML][HTML] The role of LMNA in adipose: a novel mouse model of lipodystrophy based on the Dunnigan-type familial partial lipodystrophy mutation [S]

KM Wojtanik, K Edgemon, S Viswanadha… - Journal of lipid …, 2009 - ASBMB
We investigated the role of LMNA in adipose tissue by developing a novel mouse model of
lipodystrophy. Transgenic mice were generated that express the LMNA mutation that causes …

[HTML][HTML] Calcium release-activated calcium (CRAC) channel inhibition suppresses pancreatic ductal adenocarcinoma cell proliferation and patient-derived tumor …

HY Khan, GB Mpilla, R Sexton, S Viswanadha… - Cancers, 2020 - mdpi.com
Pancreatic ductal adenocarcinoma (PDAC) remains an unmet clinical problem in urgent
need of newer molecularly driven treatment modalities. Calcium signals, particularly those …

Targeting Orai1-mediated store-operated calcium entry by RP4010 for anti-tumor activity in esophagus squamous cell carcinoma

…, S Choi, H Tran, KV Penmetsa, S Viswanadha… - Cancer letters, 2018 - Elsevier
Esophageal cancer (EC) is the 6th leading cause of cancer mortality worldwide with poor
prognosis, hence more effective chemotherapeutic drugs for this deadly disease are urgently …

Design, synthesis, and identification of silicon incorporated oxazolidinone antibiotics with improved brain exposure

…, S Veeraraghavan, S Viswanadha… - ACS Medicinal …, 2015 - ACS Publications
Therapeutic options for brain infections caused by pathogens with a reduced sensitivity to
drugs are limited. Recent reports on the potential use of linezolid in treating brain infections …

A first-in-human study of Tenalisib (RP6530), a dual PI3K δ/γ inhibitor, in patients with relapsed/refractory hematologic malignancies: Results from the European study

…, M Magagnoli, S Vakkalanka, S Viswanadha… - … Myeloma and Leukemia, 2020 - Elsevier
… Locatelli 1 , Lucia Morello 1 , Massimo Magagnoli 1 , Swaroop Vakkalanka 6 , Srikant
Viswanadha 6 , Andrés JM Ferreri 4 … Viswanadha, F. Bertoni …

Simultaneous quantification of ruxolitinib and nilotinib in rat plasma by LC–MS/MS: Application to a pharmacokinetic study

S Veeraraghavan, S Thappali, S Viswanadha… - … of Pharmaceutical and …, 2014 - Elsevier
Efficacy assessments using a combination of ruxolitinib and nilotinib necessitate the development
of a high precision analytical method for determination of both drugs in plasma. A high …